The role of cardiovascular pharmacology and therapeutics extends far beyond traditional drug regimens, encompassing groundbreaking treatments that address the intricate mechanisms of heart diseases. Recent developments include RNA-based therapies and regenerative drugs designed to repair cardiac tissue at a molecular level. Researchers are also investigating the role of anti-inflammatory agents in reducing atherosclerosis progression. Clinical trials for novel anticoagulants and lipid-lowering medications continue to refine strategies for preventing thrombotic events and improving long-term patient health. This dynamic field integrates pharmacological advances with patient-specific approaches to enhance both the efficacy and safety of cardiovascular care.
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States, United States
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, Tianjin University, China
Title : Not So Idiopathic After All: Genotype, Phenotype and IL-1 Blockade Response Converge in Recurrent Pericarditis
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Beyond the Heart in Cardiovascular Magnetic Resonance Imaging: Prevalence and Clinical Significance of Incidental Extracardiac Findings
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Cardiovascular mortality in colon cancer a patient characteristics analysis: Population-based study
Nouf, KAU, Saudi Arabia
Title : Improving Screening and Treatment of Iron Deficiency in Patients with Heart Failure with Reduced Ejection Fraction: A Two-Cycle Quality Improvement Project
Danish Malik, University Hospitals Dorset NHS Foundation Trust, United Kingdom